The Maternal Serum Preptin Levels in the Pathogenesis and Diagnosis of Gestational Diabetes Mellitus

Preptin and gestational diabetes mellitus

  • Irem KIRAÇ UTKU
  • Esra DEMIR
  • Hanişe OZKAN
  • Berrak SAHTIYANCI
  • Iskender EKINCI
  • Mitat BUYUKKABA
  • Sinem DURMUS
  • Murat AKARSU
  • Omur TABAK
  • Hafize UZUN
DOI: https://doi.org/10.5937/jomb0-36287
Keywords: Gestational diabetes mellitus, oral glucose tolerance test, preptin, insulin

Abstract


Background: Gestational diabetes mellitus (GDM) is a metabolic disorder that occurs during pregnancy that increases both maternal and fetal mortality and morbidity. We investigated whether there is a change in circulating levels of preptin, a new peptide secreted from pancreatic beta cells, due to GDM in pregnant women. The relationship between serum preptin levels with insulin and other metabolic parameters was also evaluated in these subjects. Methods: Eighty-five patients diagnosed as GDM and 89 healthy pregnant women with 75 mg oral glucose tolerance test (OGTT) was assessed in terms of serum preptin levels. Results: The serum preptin levels of the GDM group were significantly higher than those of the control group (p=0.001; p < 0.01). For the cut-off value of preptin measurement of 335.3 ng/L, the sensitivity was 97.65%, specificity was 87.64%, positive predictive value was 88.3% and negative predictive value was 97.5%. The risk of developing the disease is 294.273 times higher in patients with preptin level of 335.3 and above. Conclusions: We think that the reason for the increase in serum preptin levels in GDM is probably the response to glucose. The current results indicate that preptin plays an important role in elucidating the pathology of GDM. In addition, the search for a practical marker for the diagnosis of GDM suggests that the measurement of preptin level is promising.

References

1. Guariguata L, Linnenkamp U, Beagley J, et al. Global estimates of the prevalence of hyperglycaemia in pregnancy. Diabetes Res Clin Pract 2014; 103: 176.
2. HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarinar U, Coustan DR, et al. Hyperglycemia and adverse pregnancy outcome. N Engl J Med 2008; 358:1991-2002.
3. Cypryk K, Szymczak W, Czupryniak L, Sobczak M, Lewiński A. Gestational diabetes mellitus - an analysis of risk factors. Endokrynol Pol. 2008; 59: 393-7.
4. Chen P, Wang S, Ji J, Ge A, Chen C, Zhu Y, Xie N, Wang Y. Risk factors and management of gestational diabetes. Cell Biochem Biophys. 2015; 71:689-94.
5. ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. Obstet Gynecol 2018; 131: e49.
6. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018; 41(Suppl 1): S13-S27.
7. Lachmann EH, Fox RA, Dennison RA, Usher-Smith JA, Meek CL, Aiken CE. Barriers to completing oral glucose tolerance testing in women at risk of gestational diabetes. Diabet Med. 2020; 37:1482-1489
8. Cornish J, Callon KE, Bava U, Watson M, Xu X, Lin JM et al.. Preptin, another peptide product of the pancreatic bcell, is osteogenic in vitro and in vivo. Am J Physiol Endocrinol Metab. 2007; 292: E11722.
9. Yang G, Li L, Chen W, et al. Circulating preptin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Ann Med 2009; 41:52–6.
10. Mohammad Rahimi GR, Bijeh N, Rashidlamir A. Effects of exercise training on serum preptin, undercarboxylated osteocalcin and high molecular weight adiponectin in adults with metabolic syndrome. Exp Physiol. 2020; 105:449-459.
11. Celik N, Aydin S, Ugur K, Yardim M, Acet M, Yavuzkir S, Sahin İ, Celik O. Patatin-like phospholipase domain containing 3-gene (adiponutrin), preptin, kisspeptin and amylin regulates oocyte developmental capacity in PCOS. Cell Mol Biol (Noisy-le-grand). 2018; 64: 7-12.
12. Cai H, Liu Q, Dong X, Cai Y, Yao J, Liu Y. Plasma preptin levels are decreased in patients with essential hypertension. Pharmazie. 2018; 73: 274-278.
13. Aslan M, Celik O, Karsavuran N, et al. Maternal serum and cord blood preptin levels in gestational diabetes mellitus. J Perinatol 2011; 31, 350–355.
14. Buchanan CM, Phillips ARJ, Cooper GJS. Preptin derived from proinsulin-like growth factor II (proIGF-II) is secreted from pancreatic islet b-cells and enhances insulin secretion. Biochem J. 2001; 360: 431- 9.
15. Aydin S, Celik O, Gurates B, Sahin I, Ulas M, Yilmaz M, Kalayci M, Kuloglu T, Catak Z, Aksoy A, Ozercan IH, Kumru S. Concentrations of preptin, salusins and hepcidins in plasma and milk of lactating women with or without gestational diabetes mellitus. Peptides. 2013; 49:123-30
16. Ersahin SS, Yurci A. Cord blood and maternal serum preptin and irisin concentrations are regulated independently in GDM. Eur Rev Med Pharmacol Sci. 2021; 25:1954-1958.
17. Agarwal MM, Punnose J, Dhatt GS. Gestational diabetes: problems associated with the oral glucose tolerance test. Diabetes Res Clin Pract. 2004; 63:73-4
18. Baykus Y, Gurates B, Aydin S, Celik H, Kavak B, Aksoy A, Sahin I, Deniz R, Gungor S, Guzel SP, Minareci Y. Changes in serum obestatin, preptin and ghrelins in patients with Gestational Diabetes Mellitus. Clin Biochem. 2012; 45:198-202.
19. Aydin S. Discovery of ghrelin hormone: research and clinical applications. Turk J Biochem 2007; 32: 76–89.
Published
2022/12/01
Issue
Vol. 42 No. 2 (2023): Journal of Medical Biochemistry
Section
Original paper

Copyright (c) 2022 Irem KIRAÇ UTKU , Esra DEMIR , Hanişe OZKAN , Berrak SAHTIYANCI , Iskender EKINCI, Mitat BUYUKKABA , Sinem DURMUS, Murat AKARSU , Omur TABAK , Hafize UZUN

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.